Translate Bio, Inc. Form 8-K (Feb. 25, 2021)
Summary
Form 8-K current report of Translate Bio, Inc. dated February 25, 2021, filed under Item 2.02 (Results of Operations and Financial Condition). It reports that on February 25, 2021 the company issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2020. The press release is furnished as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Translate Bio, Inc. Form 8-K (Feb. 25, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-tbio-8-k-filed2021-02-25-0001193125-21-056938-aa9b090109/
, SHA-256 8330953402ebcbb061364f03d9efd07a6b2e734fdf569974b9f3e73bb6b1ab53.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Translate Bio, Inc. (Exact name of registrant as specified in its charter) Delaware | 001-38550 | 61-1807780 (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) 29 Hartwell Avenue Lexington , Massachusetts | 02421 (Address of principal executive offices) | (Zip Code) Registrant’s telephone number, including area code: (617) 945-7361 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class | Trading Symbol(s) | Name of exchange on which registered Common Stock, $0.001 par value | TBIO | Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 | Results of Operations and Financial Condition. On February 25, 2021, Translate Bio, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 | Financial Statements and Exhibits. (d) Exhibits Exhibit | Description of Document 99.1 | Press Release dated February 25, 2021 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSLATE BIO, INC. Date: February 25, 2021 | By: | /s/ Paul Burgess Paul Burgess Chief Operating Officer, Chief Legal Officer and Secretary
File and source
- File
- SEC_TBIO_8-K_filed2021-02-25_0001193125-21-056938.htm
- Size
- 26,234 bytes
- SHA-256
- 8330953402ebcbb061364f03d9efd07a6b2e734fdf569974b9f3e73bb6b1ab53
- Original
- www.sec.gov